WFRF:(Eliasson M)
Sökning: WFRF:(Eliasson M) > One-year treatment ...
- 5 av 386
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04146naa a2200577 4500 | |
| 001 | oai:gup.ub.gu.se/103058 | |
| 003 | SwePub | |
| 008 | 240910s2009 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://gup.ub.gu.se/publication/1030582 URI |
| 040 | a (SwePub)gu | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Bunck, M. C.4 aut |
| 245 | 1 0 | a One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial |
| 264 | 1 | c 2009 |
| 520 | a OBJECTIVE: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in beta-cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp-derived measures of beta-cell function, glycemic control, and body weight. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). beta-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period. Additional end points included effects on glycemic control, body weight, and safety. RESULTS: Treatment-induced change in combined glucose- and arginine-stimulated C-peptide secretion was 2.46-fold (95% CI 2.09-2.90, P < 0.0001) greater after a 52-week exenatide treatment compared with insulin glargine treatment. Both exenatide and insulin glargine reduced A1C similarly: -0.8 +/- 0.1 and -0.7 +/- 0.2%, respectively (P = 0.55). Exenatide reduced body weight compared with insulin glargine (difference -4.6 kg, P < 0.0001). beta-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period. A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy. CONCLUSIONS: Exenatide significantly improves beta-cell function during 1 year of treatment compared with titrated insulin glargine. After cessation of both exenatide and insulin glargine therapy, beta-cell function and glycemic control returned to pretreatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therapy. | |
| 653 | a Arginine/pharmacology | |
| 653 | a Blood Glucose/metabolism | |
| 653 | a Body Mass Index | |
| 653 | a C-Peptide/blood | |
| 653 | a Diabetes Mellitus | |
| 653 | a Type 2/blood/*drug therapy/physiopathology | |
| 653 | a Female | |
| 653 | a Hemoglobin A | |
| 653 | a Glycosylated/metabolism | |
| 653 | a Humans | |
| 653 | a Hypoglycemic Agents/*therapeutic use | |
| 653 | a Insulin/*analogs & derivatives/*secretion/therapeutic use | |
| 653 | a Insulin-Secreting Cells/drug effects/*physiology | |
| 653 | a Kinetics | |
| 653 | a Male | |
| 653 | a Metformin/*therapeutic use | |
| 653 | a Middle Aged | |
| 653 | a Peptides/*therapeutic use | |
| 653 | a Venoms/*therapeutic use | |
| 700 | 1 | a Diamant, M.4 aut |
| 700 | 1 | a Corner, A.4 aut |
| 700 | 1 | a Eliasson, Björn,d 1959u Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine4 aut0 (Swepub:gu)xelibj |
| 700 | 1 | a Malloy, J. L.4 aut |
| 700 | 1 | a Shaginian, R. M.4 aut |
| 700 | 1 | a Deng, W.4 aut |
| 700 | 1 | a Kendall, D. M.4 aut |
| 700 | 1 | a Taskinen, M. R.4 aut |
| 700 | 1 | a Smith, Ulf,d 1943u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xsmiul |
| 700 | 1 | a Yki-Jarvinen, H.4 aut |
| 700 | 1 | a Heine, R. J.4 aut |
| 710 | 2 | a Göteborgs universitetb Institutionen för medicin4 org |
| 773 | 0 | t Diabetes Careg 32:5, s. 762-8q 32:5<762-8x 1935-5548 |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/103058 |
- 5 av 386
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Bunck, M. C.
- Diamant, M.
- Corner, A.
- Eliasson, Björn, ...
- Malloy, J. L.
- Shaginian, R. M.
- visa fler...
- Deng, W.
- Kendall, D. M.
- Taskinen, M. R.
- Smith, Ulf, 1943
- Yki-Jarvinen, H.
- Heine, R. J.
- visa färre...
- Artiklar i publikationen
- Diabetes Care
- Av lärosätet
- Göteborgs universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
